Correction to: Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsOcular Oncology and Treatments · Retinal Development and Disorders · Ocular Disorders and Treatments
This is a correction to: Tristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, Antoine Desilets, Rino Seedor, Marlana Orloff, Takami Sato, Michael Caplan, Mariam El-Ashmawy, Benjamin Izar, Shaheer Khan, Inderjit Mehmi, Aleigha Lawless, Theodore S Hong, Omid Hamid, Richard D Carvajal, Alexander Shoushtari, Ryan J Sullivan, Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients, The Oncologist, Volume 30, Issue 10, October 2025, oyaf323, https://doi.org/10.1093/oncolo/oyaf323
In the originally published version of the paper, Figure 1A had incorrect legend labels. “Systemic” and “Hepatic Only” are corrected to read: “Tebentafusp + CLT (PFS1+PFS2)” and “Tebentafusp (PFS1)”, respectively.
Figure 1 should read:
instead of: